Kotak Bank, NCC & Cipla in Focus on Key Updates

: The bank has submitted Anup Saha and Rohan Kashyap as CEO candidates to the Reserve Bank of India (RBI). The development is important from a leadership and governance perspective as the bank moves through the process of selecting its next chief executive. Investors will track the RBI’s decision and any further developments regarding the appointment. IMPACT Neutral NCC: The company received three orders worth ₹430.19 crore during August, strengthening its order inflow and adding to its infrastructure project pipeline. Fresh orders provide additional execution visibility and support the company’s revenue outlook. IMPACT POSITIVE Cipla: The company has entered into an exclusive licensing and supply agreement with Chia Tai Tianqing Pharmaceutical Group (CTTQ), an arm of SBP Group, for Rolditamig Deuderuxtecan (TQB2102). Cipla will receive exclusive rights to develop and commercialise the oncology drug in India, South Africa and five other emerging markets, while CTTQ will manufacture and supply the therapy. The drug is being evaluated for HER2-expressing cancers. IMAPCT POSITIVE